ORCHPHARMA Orchid Pharma Q4 FY25 results (Jan–Mar 2025) and concall
Orchid Pharma reported a 9% YoY sales growth to Rs. 237 crores and an EBITDA of Rs. 40 crores for Q4 FY25. Full-year FY25 sales grew 13% to Rs. 922 crores with an EBITDA of Rs. 156 crores. Key projects like 7-ACA faced delays, pushing commercialization to March 2027, while Enmetazobactam showed strong traction in India. The company anticipates a muted FY26 due to pricing pressures and CAPEX, but expects the merged Dhanuka Laboratories entity to provide a stronger platform with over Rs. 1,500 crore revenue.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 223 | 217 | 237 |
| EBITDA | 30 | 26 | 28 |
| Net profit | 27 | 21 | 22 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
